Autologous dendritic cell vaccine
A vaccine made from your own dendritic cells, trained against your own tumour markers.
Dendritic cells are the immune system’s messengers. In this approach they are collected from the patient, loaded with tumour-associated signals, matured outside the body and returned — with the aim of teaching T cells what to look for.
It is delivered as part of a supervised plan, usually alongside standard treatment rather than instead of it. Each preparation is patient-specific, which is why the assessment and laboratory timeline come before any scheduling conversation.
What it does not do
- This is an individualised preparation, not an off-the-shelf product. Quality and timing depend on the laboratory and on the patient's own cells.
- Response varies and cannot be predicted in advance. No outcome is guaranteed by the hospital or by us.
- It is not offered as a first-line alternative to surgery, chemotherapy, radiotherapy or approved targeted therapy.
These limits are written by us, not by the hospital. If a provider presents this therapy without any of them, treat that as a warning sign.
| Indication | Selected solid tumours, as part of an individualised plan |
| Approved in | China — biomedical new-technology pathway |
| Status in China | Approved clinical translation project within the zone |
| Assessment required | Yes — physician assessment first |
| Delivered at | 2 hospital(s) |
Delivered at
West China Lecheng Hospital
Carries a large share of the zone's approved biomedical new-technology projects across oncology, rare disease, autoimmune conditions, ophthalmology and joints.
Shulan (Boao) Hospital
Where the zone's autologous NK-cell and activated T-lymphocyte programmes are delivered, with a strong hepatobiliary surgery base behind them.
Also in Oncology
BNCT
A targeted radiotherapy that delivers its dose cell-by-cell, sparing the tissue around it.
Histotripsy
Tumour tissue broken down by focused ultrasound — no incision, no needle, no radiation.
NK cell therapy
Expanded natural-killer cells, given after surgery to widen the immune margin.
Tell us the therapy by name, and we will check it.
Availability moves with batches and indications. A two-line enquiry is enough for us to confirm whether it is reachable this quarter.